Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

Cited In for PubMed (Select 20406929)

1.

Familial breast cancer - targeted therapy in secondary and tertiary prevention.

Kast K, Rhiem K.

Breast Care (Basel). 2015 Feb;10(1):27-31. doi: 10.1159/000380756. Review.

PMID:
25960722
2.

Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations.

Silva JG, Corrales-Medina FF, Maher OM, Tannir N, Huh WW, Rytting ME, Subbiah V.

Oncoscience. 2015 Feb 20;2(2):187-92. eCollection 2015.

3.

Consequence of the tumor-associated conversion to cyclin D1b.

Augello MA, Berman-Booty LD, Carr R 3rd, Yoshida A, Dean JL, Schiewer MJ, Feng FY, Tomlins SA, Gao E, Koch WJ, Benovic JL, Diehl JA, Knudsen KE.

EMBO Mol Med. 2015 Mar 18;7(5):628-47. doi: 10.15252/emmm.201404242.

4.

An update on PARP inhibitors for the treatment of cancer.

Benafif S, Hall M.

Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015. Review.

5.

New perspectives on targeted therapy in ovarian cancer.

Coward JI, Middleton K, Murphy F.

Int J Womens Health. 2015 Feb 4;7:189-203. doi: 10.2147/IJWH.S52379. eCollection 2015. Review.

6.

A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.

Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA.

Cancer Res. 2015 Feb 15;75(4):628-34. doi: 10.1158/0008-5472.CAN-14-2593. Epub 2015 Jan 29.

7.

Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening.

Zhou Z, Patel M, Ng N, Hsieh MH, Orth AP, Walker JR, Batalov S, Harris JL, Liu J.

BMC Cancer. 2014 Dec 13;14:944. doi: 10.1186/1471-2407-14-944.

8.

Pan-cancer patterns of DNA methylation.

Witte T, Plass C, Gerhauser C.

Genome Med. 2014 Aug 30;6(8):66. doi: 10.1186/s13073-014-0066-6. eCollection 2014.

9.

Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer.

Terlikowska KM, Witkowska AM, Zujko ME, Dobrzycka B, Terlikowski SJ.

Int J Mol Sci. 2014 Nov 25;15(12):21703-22. doi: 10.3390/ijms151221703. Review.

10.

RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization.

Young A, Berry R, Holloway AF, Blackburn NB, Dickinson JL, Skala M, Phillips JL, Brettingham-Moore KH.

BMC Cancer. 2014 Nov 4;14:808. doi: 10.1186/1471-2407-14-808.

11.

Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing.

Ratajska M, Krygier M, Stukan M, Kuźniacka A, Koczkowska M, Dudziak M, Śniadecki M, Dębniak J, Wydra D, Brozek I, Biernat W, Borg A, Limon J, Wasąg B.

J Appl Genet. 2015 May;56(2):193-8. doi: 10.1007/s13353-014-0254-5. Epub 2014 Nov 1.

12.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ.

Pediatr Blood Cancer. 2015 Jan;62(1):91-8. doi: 10.1002/pbc.25201. Epub 2014 Sep 27.

PMID:
25263539
13.

Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.

Nickerson ML, Dancik GM, Im KM, Edwards MG, Turan S, Brown J, Ruiz-Rodriguez C, Owens C, Costello JC, Guo G, Tsang SX, Li Y, Zhou Q, Cai Z, Moore LE, Lucia MS, Dean M, Theodorescu D.

Clin Cancer Res. 2014 Sep 15;20(18):4935-48. doi: 10.1158/1078-0432.CCR-14-0330.

PMID:
25225064
14.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA.

Lancet Oncol. 2014 Oct;15(11):1207-14. doi: 10.1016/S1470-2045(14)70391-2. Epub 2014 Sep 10.

PMID:
25218906
15.

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.

Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY.

Cancer Med. 2014 Dec;3(6):1579-94. doi: 10.1002/cam4.317. Epub 2014 Aug 13.

16.

Mutational landscape of candidate genes in familial prostate cancer.

Johnson AM, Zuhlke KA, Plotts C, McDonnell SK, Middha S, Riska SM, Schaid DJ, Thibodeau SN, Douglas JA, Cooney KA.

Prostate. 2014 Oct;74(14):1371-8. doi: 10.1002/pros.22849. Epub 2014 Aug 11.

PMID:
25111073
17.

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.

Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L.

Br J Cancer. 2014 Aug 12;111(4):651-9. doi: 10.1038/bjc.2014.345. Epub 2014 Jul 15.

PMID:
25025963
18.

The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer.

Khabele D.

Front Oncol. 2014 May 20;4:111. doi: 10.3389/fonc.2014.00111. eCollection 2014. Review.

19.

Development of synthetic lethality anticancer therapeutics.

Fang B.

J Med Chem. 2014 Oct 9;57(19):7859-73. doi: 10.1021/jm500415t. Epub 2014 Jun 13. Review.

20.

Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples.

Patterson MJ, Sutton RE, Forrest I, Sharrock R, Lane M, Kaufmann A, O'Donnell R, Edmondson RJ, Wilson BT, Curtin NJ.

Br J Cancer. 2014 Jul 8;111(1):94-100. doi: 10.1038/bjc.2014.261. Epub 2014 May 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk